Rosetta Genomics Ltd. (NASDAQ:ROSG) has been assigned a consensus broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. Rosetta Genomics’ rating score has declined by 100% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 1-year consensus price objective of $2.05 for the company, according to Zacks. Zacks has also assigned Rosetta Genomics an industry rank of 113 out of 265 based on the ratings given to its competitors.
Separately, Barrington Research downgraded shares of Rosetta Genomics from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th.
Shares of Rosetta Genomics (ROSG) traded down $0.01 during midday trading on Tuesday, reaching $0.56. 136,513 shares of the company traded hands, compared to its average volume of 147,751. The company has a market capitalization of $1.72, a price-to-earnings ratio of -0.06 and a beta of 0.31. Rosetta Genomics has a fifty-two week low of $0.48 and a fifty-two week high of $6.96. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.10 and a current ratio of 2.10.
WARNING: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/zacks-rosetta-genomics-ltd-rosg-receives-consensus-recommendation-of-buy-from-analysts.html.
About Rosetta Genomics
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
Get a free copy of the Zacks research report on Rosetta Genomics (ROSG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.